Hemoglobin and Neutrophil Count as Prognostic Factors in Cholangiocarcinoma Patients in 2nd Line Treatment Setting: Results from a Small Monocentric Retrospective Study
Background: Unresectable cholangiocarcinoma prognosis can be extremely variable due to different symptoms and sites of disease involvement at diagnosis and unpredictable chemotherapy response rates. Most patients will usually receive 1st line palliative chemotherapy with platinum compounds and Gemci...
Main Authors: | Carolina Liguori, Cecilia Copparoni, Cristiano Felicetti, Federica Pecci, Alessio Lupi, Giada Pinterpe, Rossana Berardi, Riccardo Giampieri |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-01-01
|
Series: | Current Oncology |
Subjects: | |
Online Access: | https://www.mdpi.com/1718-7729/30/1/79 |
Similar Items
-
Locoregional Treatments in Cholangiocarcinoma and Combined Hepatocellular Cholangiocarcinoma
by: Matteo Renzulli, et al.
Published: (2021-07-01) -
The Landscape of ALK-Rearranged Non-Small Cell Lung Cancer: A Comprehensive Review of Clinicopathologic, Genomic Characteristics, and Therapeutic Perspectives
by: Valeria Cognigni, et al.
Published: (2022-09-01) -
Association of Blood Leukocytes and Hemoglobin with Hospital Mortality in Acute Pulmonary Embolism
by: Slobodan Obradovic, et al.
Published: (2023-09-01) -
Interventional Treatment Strategies in Intrahepatic Cholangiocarcinoma and Perspectives for Combined Hepatocellular-Cholangiocarcinoma
by: Timo Alexander Auer, et al.
Published: (2023-05-01) -
Diagnosis of Cholangiocarcinoma
by: Dong Woo Shin, et al.
Published: (2023-01-01)